Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rubius Therapeutics, Inc. (RUBY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7999+0.0418 (+5.51%)
At close: 04:00PM EDT
0.8070 +0.01 (+0.89%)
After hours: 07:47PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Zacks

    Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?

    Rubius Therapeutics, Inc. (RUBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

    New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H’22 from Phase 1 Arm of RTX-240 + Pembrolizumab in Advanced Solid Tumors and Expansion Cohorts in Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Dose Escalation Continues in Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date; Initial

  • GlobeNewswire

    Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

    CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open. The company will not be hosting a teleconference in conjunction

Advertisement
Advertisement